Ewing's U: Dr. Rashmi Chugh: Phase 1 INBRX-109 Trial

Ewing's U
Written By Alana Arens

Dr. Rashmi Chugh (University of Michigan) presents a phase I trial for Ewing sarcoma, centered around a new targeted agent called INBRX-109. INBRX-109 is a recombinant humanized tetravalent antibody targeting human death receptor 5 (DR5). This targeted agent will be given in combination with Irinotecan and Temozolomide.

Alana Arens
Previous

Advancing ctDNA Testing for Ewing Sarcoma: A New Grant to DFCI

Next

Ewing’s U: Dr. Matteo Trucco: New METTSEO Clinical Trial for Metastatic Ewing Sarcoma